Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -454.54k | 75.70% |
| EBITDA | -180.89k | 85.50% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €242.37k |
Number of shares | 11.62m |
52-week high/low | €0.16 - €0.02 |
| Dividends | No |
Beta | 0.30 |
P/E ratio | -0.39 |
PEG ratio | -0.01 |
P/B ratio | -0.07 |
P/S ratio | 0.00 |
Company profile
EGF Theramed Health Corp. provides psychedelic drugs for the treatment of mental health. It offers psychedelics for the treatment of conditions, such as treatment-resistant depression, anxiety, PTSD, and depression. The company was incorporated in 2011 and is headquartered in Vancouver, Canada.
| Name | EGF Theramed Health Aktie |
| CEO | Kevin da Costa |
| Headquarters | Vancouver,
bc Canada |
| Website | |
| IPO | 01/03/2017 |
| Employees | 2,500 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | EVAHF |
Cnq | TMED.CN |
Frankfurt | AUH.F |
München | AUH.MU |
